Dynavax (DVAX) Tops Q3 EPS by 14c; Offers FY23 Revenue Guidance

Dynavax (NASDAQ: DVAX) reported Q3 EPS of $0.10, $0.14 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $69.51 million versus the consensus estimate of $60.3 million.

GUIDANCE:

Dynavax sees FY2023 revenue of $210-220 million, versus the consensus of $224.7 million.

For earnings history and earnings-related data on Dynavax (DVAX) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• McCormick & Co. (MKC) Tops Q3 EPS by 10c, Beats on Revenue; Offers EPS Guidance
• Integra LifeSciences stock tumbles after cutting 2026 outlook